Onderneming Melinta Therapeutics Inc Nasdaq
Aandelen
US58549G1004
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 03-08-20 | |
Susan Blum
DFI | Director of Finance/CFO | 52 | 01-01-16 |
Compliance Officer | 45 | - | |
Jisoo Park
PRN | Corporate Officer/Principal | - | 06-07-21 |
Kristen Allgor
HRO | Human Resources Officer | - | 16-11-20 |
John Harlow
PRN | Corporate Officer/Principal | - | 30-03-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jonathan Leff
BRD | Director/Board Member | 55 | 20-04-20 |
Director/Board Member | - | 20-04-20 | |
Director/Board Member | - | 20-04-20 | |
Compliance Officer | 45 | - | |
Chief Executive Officer | 48 | 03-08-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 13 750 691 | 13 578 334 ( 98,75 %) | 0 | 98,75 % |
Bedrijfsgegevens
Melinta Therapeutics, Inc.
389 Interpace Parkway Suite 450
07054, Parsippany
+908-617-1300
http://melinta.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,97% | 108 mld. | |
+10,21% | 105 mld. | |
+1,57% | 23,46 mld. | |
-12,77% | 21,72 mld. | |
-7,05% | 18,64 mld. | |
-37,64% | 17,45 mld. | |
-6,50% | 17,19 mld. | |
+6,00% | 13,99 mld. | |
+37,20% | 12,53 mld. |